# ERA4Health Joint Transnational Call – IICS4all

**Funder:** European Commission
**Deadline:** 14 January 2027
**Consortium:** Required — multi-national consortium of clinical/public health teams conducting transnational Investigator-Initiated Clinical Studies across multiple countries
**Frequency:** Annual
**Official call:** https://era4health.eu/calls/pre_iics4all2027.php
**Last updated:** 8 Nov 2026

## Eligibility & scope

Funds multi-national Investigator-Initiated Clinical Studies (IICS) in cardiovascular, autoimmune, metabolic and non-communicable respiratory diseases, including underrepresented populations. Studies should be pragmatic comparative effectiveness and/or drug repurposing trials of off-patent drugs demonstrating transnational collaboration across countries.

## Summary

The ERA4Health IICS4all Joint Transnational Call funds multi-national Investigator-Initiated Clinical Studies in cardiovascular, autoimmune, metabolic and non-communicable respiratory diseases. It targets pragmatic comparative effectiveness trials and drug repurposing studies of off-patent drugs, run by transnational consortia of clinical and public health researchers, with attention to underrepresented populations. The call runs annually under the European Commission's ERA4Health partnership.

## Who should apply

- Clinical and public health researchers leading investigator-initiated trials
- Multi-national consortia spanning clinical research teams across countries
- Research focus on cardiovascular, autoimmune, metabolic or non-communicable respiratory disease
- Teams designing pragmatic comparative effectiveness or drug repurposing trials of off-patent drugs
- Studies including underrepresented patient populations

## Key dates

- Deadline: 14 January 2027
- Call runs annually under ERA4Health

## Tips for applicants

- Frame the trial design explicitly as pragmatic comparative effectiveness or drug repurposing, the call excludes standard drug-development trials.
- Build the consortium around off-patent drug use cases, since novel compound trials fall outside scope.
- Show concrete inclusion of underrepresented populations in the study design, not just as a stated aim.

## Frequently asked questions

### What diseases does the ERA4Health IICS4all call fund?

Cardiovascular, autoimmune, metabolic and non-communicable respiratory diseases, including studies involving underrepresented populations.

### What type of clinical studies does IICS4all support?

Pragmatic comparative effectiveness trials and drug repurposing trials of off-patent drugs led by investigators rather than industry.

### Is a consortium required for ERA4Health IICS4all?

Yes, applicants must form a multi-national consortium of clinical and public health teams conducting the study across multiple countries.

### When is the ERA4Health IICS4all deadline?

The deadline is 14 January 2027, and the call runs annually.

---

Source: [The Great Grantsby](https://grantsby.eu/grants/european-commission-era4health-joint-transnational-call-iics4all-2027-01) — EU grant monitoring for academic researchers. Always verify details on the funder's website before applying.

**See which EU calls match your profile.** [Preview your matches in 30 seconds, no signup](https://grantsby.eu/demo?ref=llm_grant_md&grant=european-commission-era4health-joint-transnational-call-iics4all-2027-01).